vTv Therapeutics is a clinical stage biopharmaceutical company with a pipeline of first-in-class small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of diseases led by programs for the treatment of type 1 diabetes and Alzheimer’s disease. vTv has a long history of innovation and has discovered all of these molecules in-house. There are nearly 1.5 million people with type 1 diabetes in the US with no treatment options beyond insulin and amylin injections. TTP399 was originally developed for the treatment of type 2 diabetes, but vTv found a greater need for new treatment options for type 1 diabetes. TTP399 has an insulin-independent MOA, which makes it uniquely suited to type 1 diabetes.